BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Jacobio Pharma Strikes Global Deal With AstraZeneca For Pan KRAS Inhibitor JAB 23E73

Jacobio Pharma announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive ...

December 23, 2025 | News

Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...

December 23, 2025 | News

Alphamab Oncology’s JSKN003 Gains FDA Breakthrough Therapy Designation For Platinum Resistant Ovarian Cancer

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the...

December 23, 2025 | News

Qihan Biotech Initiates Phase I IIa Dosing Of Allogeneic CAR T Therapy For Refractory Lupus

Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-...

December 22, 2025 | News

Harbour BioMed Enters Global Antibody Collaboration With Bristol Myers Squibb

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...

December 18, 2025 | News

Everest Medicines Secures FDA Approval For LEROCHOL In Hypercholesterolemia

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

December 18, 2025 | News

Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA ...

December 18, 2025 | News

Eccogene Enrols First Patient In Phase 2a MOSAIC Trial For MASH Therapies

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammato...

December 18, 2025 | News

GenSci, RTW And Yarrow Forge US Focused Biotech Partnership To Advance First In Class Thyroid Autoimmune Therapy

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology di...

December 17, 2025 | News

Peijia Medical Secures China Regulatory Approval For TaurusTrio Transcatheter Aortic Valve System

Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, a...

December 16, 2025 | News

Everest Medicines Enters Dual Strategic Agreements with Hasten to Drive Accretive Growth

- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveragi...

December 15, 2025 | News

Insilico Medicine Partners with TaiGen to Accelerate AI-Driven Anemia Therapy in Greater China

Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM48...

December 15, 2025 | News

Zealand Pharma And OTR Therapeutics Forge Strategic Collaboration To Advance Next Generation Metabolic Therapies

Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and...

December 12, 2025 | News

Formation Bio Acquires Global Rights To CNS Penetrant TYK2 Inhibitor LNK01006

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio announced Formation Bio's acquisition of wor...

December 11, 2025 | News

Stay Connected